ABSTRACT
Increased left ventricular (LV) mass (LVM) and LV hypertrophy (LVH) are risk markers for adverse cardiovascular events, and may indicate an underlying cardiomyopathy. Cardiac magnetic resonance (CMR) is the gold standard for LVM estimation, but is challenging to obtain at scale, which has limited the power of prior genetic analyses. In the current study, we performed a genome-wide association study (GWAS) of CMR-derived LVM indexed to body surface area (LVMI) estimated using a deep learning algorithm within nearly 50,000 participants from the UK Biobank. We identified 12 independent associations (1 known at TTN and 11 novel) meeting genome-wide significance, implicating several candidate genes previously associated with cardiac contractility and cardiomyopathy. Greater CMR-derived LVMI was associated with higher risk of incident dilated (hazard ratio [HR] 2.58 per 1-SD increase, 95% CI 2.10-3.17) and hypertrophic (HR 2.62, 95% CI 2.09-3.30) cardiomyopathies. A polygenic risk score (PRS) for LVMI was also associated with incident hypertrophic cardiomyopathy within a separate set of UK Biobank participants (HR 1.12, 95% CI 1.01-1.12) and among individuals in an external Mass General Brigham dataset (HR 1.18, 95% CI 1.01-1.37). In summary, using CMR-derived LVM available at scale, we have identified 12 common variants associated with LVMI (11 novel) and demonstrated that both CMR-derived and genetically determined LVMI are associated with risk of incident cardiomyopathy.
Journal Subject Terms machine learning, left ventricular hypertrophy, genetics
Competing Interest Statement
Dr. Pirruccello has consulted for Maze Therapeutics. Dr. Friedman receives research support from Bayer AG and IBM. Dr. Weng receives sponsored research support from IBM to the Broad Institute. Dr. Anderson receives research support from Bayer AG and has consulted for ApoPharma, Inc. Dr. Batra receives research support from Bayer AG and IBM, and consults for Novartis. Dr. Ho receives research support from Bayer AG and Gilead Sciences, and has received research supplies from EcoNugenics. Dr. Philippakis receives research support from Bayer AG, IBM, Intel, and Verily, and has consulted for Novartis and Rakuten. Dr. Ellinor receives research support from Bayer AG, and has consulted for Bayer AG, Novartis, MyoKardia and Quest Diagnostics. Dr. Lubitz receives research support from Bristol Myers Squibb/Pfizer, Bayer AG, Boehringer Ingelheim, and Fitbit, and has consulted for Bristol Myers Squibb/Pfizer and Bayer AG, and participates in a research collaboration with IBM.
Funding Statement
Dr. Pirruccello is supported by a John S. LaDue Memorial Fellowship. Dr. Weng is supported by NIH 1R01HL139731. Dr. Choi is supported by the NIH NHLBI BioData Catalyst Fellows program. Dr. Ho is supported by NIH R01HL134893, R01HL140224, and K24HL153669. Dr. Lubitz is supported by NIH 1R01HL139731 and American Heart Association 18SFRN34250007. Dr. Ellinor is supported by NIH 1R01HL092577, R01HL128914, and K24HL105780, American Heart Association 18SFRN34110082, and the Foundation Leducq 14CVD01. Dr. Nauffal is supported by NIH T32HL007604.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UK Biobank and MGB Biobank participants provided written informed consent. The UK Biobank was approved by the UK Biobank Research Ethics Committee (reference number 11/NW/0382) and the MGB Biobank by the MGB Institutional Review Board. Use of UK Biobank (application #17488) and MGB Biobank data were approved by the local MGB Institutional Review Board.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
UK Biobank data are publicly available by application (www.ukbiobank.ac.uk). MGB data contain protected health information and cannot be shared publicly. Data processing scripts used to perform the analyses described herein are available at https://github.com/shaankhurshid/lvmass_gwas.
